VIPhyb

VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis[1][2][3][4].

Product Specifications

CAS Number

[125093-93-8]

UNSPSC

12352209

Target

CMV; PD-1/PD-L1

Type

Peptides

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/viphyb.html

Purity

99.73

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CC(N)=O)=O)=O)=O)=O)=O)=O)CC2=CC=C(C=C2)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)=O)NC([C@H]4N(CCC4)C([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H]5N(CCC5)C([C@@H](N)CCCCN)=O)=O)=O)=O)=O

Molecular Formula

C154H257N49O40S

Molecular Weight

3467.06

References & Citations

[1]Moody TW, et al. (Stearyl, Norleucine17) VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells. Life Sci. 1997;61 (17) :1657-66.|[2]Li JM, et al. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice. PLoS One. 2013 May 27;8 (5) :e63381.|[3]Vu JP, et al. Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS) -induced colitis in mice. J Mol Neurosci. 2014 Jan;52 (1) :37-47.|[4]Emily R Summerbell, et al. Blocking VIP Signaling Abrogates Upregulation Of PD1 and Increases Proliferation Of Allo-Reactive T-Cells In a Mixed Lymphocyte Reaction, Blood, Volume 122, Issue 21, 2013, Page 1041.